Currently, there are 184.53M common shares owned by the public and among those 182.22M shares have been available to trade.
The company’s stock has a 5-day price change of 0.10% and -35.12% over the past three months. EXAS shares are trading -44.08% year to date (YTD), with the 12-month market performance down to -55.33% lower. It has a 12-month low price of $41.08 and touched a high of $100.77 over the same period. EXAS has an average intraday trading volume of 3.21 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -5.94%, -21.79%, and -33.95% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Exact Sciences Corp. (NASDAQ: EXAS) shares accounts for 89.63% of the company’s 184.53M shares outstanding.
It has a market capitalization of $7.63B and a beta (3y monthly) value of 1.23. The earnings-per-share (ttm) stands at -$1.32. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.85% over the week and 4.75% over the month.
Earnings per share for the fiscal year are expected to decrease by -1.17%, and 97.99% over the next financial year.
Looking at the support for the EXAS, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on June 03, 2024, with the firm’s price target at $75. The Benchmark Company coverage for the Exact Sciences Corp. (EXAS) stock in a research note released on January 02, 2024 offered a Buy rating with a price target of $91. Guggenheim was of a view on December 14, 2023 that the stock is Buy, while Wolfe Research gave the stock Outperform rating on December 13, 2023, issuing a price target of $95. Piper Sandler on their part issued Overweight rating on October 10, 2023.
